ArticleData in brief2019
Data on a novel liver bioscaffold (rDLS) generated from regenerative liver with activated extracellular matrix for functional liver regeneration.
Article in Data in brief, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Liver scaffolds obtained by decellularization: A transplant perspective in liver bioengineering.Journal of tissue engineeringArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The data presented in this article are related to the original research article entitled "A novel bioscaffold with naturally-occurring extracellular matrix promotes hepatocyte survival and vessel patency in mouse models of heterologous transplantation" (Yang et al., in press) [1]. This article describes a decellularized liver scaffold (DLS) that derived from partial hepatectomy liver (rDLS) which supported primary hepatocyte survival and promoted blood patency, as compared with a conventional scaffold that generated from naïve liver (nDLS). Analysis by immunochemistry and scanning electron microscope (SEM) showed that the vessel network and extracellular matrix (ECM) components were similar to the nDLS. The rDLS could prevent blood clotting after transplanted it in vivo, identified by immunofluorescence staining for the integrin (αIIb, α4) expression and liver transplantation models (mice, pigs) a formed well-blood petency liver lobules. These data indicate that the novel scaffold (rDLS) with naturally-occurring "activated ECM" that may be useful for the implantation in vivo of a bioengineered organoid that is able to exert function long term without clotting in future clinic.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.